Paper17545614
Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
Sui M and 4 others. Cancer Res, 2007. Cited by 87 papers, by iCite.
Cite this record
ConductScience Library. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Papers, record 17545614. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17545614
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Estrogen Receptor alpha | Major topic |
| Paclitaxel | Major topic |
| Antineoplastic Agents, Phytogenic | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Apoptosis | |
| Cell Line, Tumor | |
| Drug Resistance, Neoplasm | |
| Drug Synergism | |
| Estradiol | |
| Fulvestrant | |
| Humans | |
| Microtubules | |
| Mitosis | |
| Prohibitins | |
| Transfection |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA109274 | NCI NIH HHS | United States | R01CA109274 | PubMed and NIH | NIH RePORTER |
| CA88843 | NCI NIH HHS | United States | P50CA088843 | PubMed and NIH | NIH RePORTER |
| CA92280 | NCI NIH HHS | United States | R01CA092280 | PubMed and NIH | NIH RePORTER |
| R55CA109274 | NIH | NIH RePORTER |
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 87 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40958617 | Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer. | Ann Med | 2025 | https://conductscience.org/library/papers/40958617 | PubMed |
| 40176396 | Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data. | Thorac Cancer | 2025 | https://conductscience.org/library/papers/40176396 | PubMed |
| 38851818 | Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. | NPJ Breast Cancer | 2024 | https://conductscience.org/library/papers/38851818 | PubMed |
| 38393465 | The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast. | Mol Biol Rep | 2024 | https://conductscience.org/library/papers/38393465 | PubMed |
| 38187046 | Estrogen receptor α inhibits Caveolin 1 translation by promoting m6A-dependent miR199a-5p maturation to confer nab-paclitaxel resistance. | Am J Cancer Res | 2023 | https://conductscience.org/library/papers/38187046 | PubMed |
| 36241702 | Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway. | Cancer Gene Ther | 2023 | https://conductscience.org/library/papers/36241702 | PubMed |
| 33207722 | Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer. | Brain Sci | 2020 | https://conductscience.org/library/papers/33207722 | PubMed |
| 32975708 | Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations. | Breast Cancer Res Treat | 2021 | https://conductscience.org/library/papers/32975708 | PubMed |
| 32781533 | Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32781533 | PubMed |
| 32765594 | Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis. | Front Genet | 2020 | https://conductscience.org/library/papers/32765594 | PubMed |
| 32158193 | NVP-BSK805, an Inhibitor of JAK2 Kinase, Significantly Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma in vitro and in vivo. | Drug Des Devel Ther | 2020 | https://conductscience.org/library/papers/32158193 | PubMed |
| 30937657 | 4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion. | Breast Cancer Res Treat | 2019 | https://conductscience.org/library/papers/30937657 | PubMed |
| 30179299 | Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells. | J Cell Mol Med | 2018 | https://conductscience.org/library/papers/30179299 | PubMed |
| 29937544 | Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription. | Br J Cancer | 2018 | https://conductscience.org/library/papers/29937544 | PubMed |
| 29430288 | Synthesis and Biological Evaluations of Ring Substituted Tetrahydroisoquinolines (THIQs) as Anti-Breast Cancer Agents. | J Cancer Sci Ther | 2017 | https://conductscience.org/library/papers/29430288 | PubMed |
| 29373839 | Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. | Cancer Lett | 2018 | https://conductscience.org/library/papers/29373839 | PubMed |
| 28747642 | A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. | Sci Rep | 2017 | https://conductscience.org/library/papers/28747642 | PubMed |
| 28081544 | Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. | Br J Cancer | 2017 | https://conductscience.org/library/papers/28081544 | PubMed |
| 28000875 | Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression. | Oncol Rep | 2017 | https://conductscience.org/library/papers/28000875 | PubMed |
| 27845892 | LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. | Oncotarget | 2016 | https://conductscience.org/library/papers/27845892 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17545614
GET https://conductscience.org/api/papers/v1/17545614/cited_by?page=2